RxDoctor Payments Data

Marianna Siksay

Family Medicine · Owatonna, MNNPI 1780652420

Payments from drug & device makers

$1,116in general payments, 2019–2025

Across 46 payments — averaging $24.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$416
  • Novo Nordisk$307
  • Abbott$121
  • Astellas Pharma US Inc$102
  • Lilly USA, LLC$60
  • Akcea Therapeutics, Inc.$44
  • plus $65 from 3 others

What the payments were for

  • Food & beverage$1,116100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,116 in reported general payments places this provider in the 90th percentile of 1,162 family medicine providers in Minnesota.

See all family medicine providers in Minnesota

Medicare billing

Part B allowed, 2024
$207,757
Medicare patients
784
Services billed
2,642

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide50$64,489
JardianceEmpagliflozin57$55,726
MounjaroTirzepatide30$38,904
EliquisApixaban29$32,982
FarxigaDapagliflozin Propanediol14$18,625
MyrbetriqMirabegron14$14,797
LinzessLinaclotide12$9,222
TradjentaLinagliptin12$9,032
Aimovig AutoinjectorErenumab-Aooe11$8,144
BrilintaTicagrelor13$5,513
Estradiol56$4,056
Valsartan112$3,984
SynthroidLevothyroxine Sodium41$2,891
Wixela InhubFluticasone Propion/Salmeterol18$2,708
Rosuvastatin Calcium209$2,333

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$307$64,48950 claims
Lilly USA, LLCMounjaro$60$38,90430 claims
AstraZenecaFarxiga, Brilinta$16$24,13827 claims
Astellas Pharma US IncMyrbetriq$102$14,79714 claims
AbbVieLinzess, Synthroid$416$12,11353 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,162 family medicine providers in Minnesota.

Other family medicine in Owatonna

See the full list for Minnesota

Where these figures come from

Is this you, or does something look wrong? →